Search results for " onset"

showing 10 items of 418 documents

Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis

2020

Abstract An ever-expanding number of disease-modifying drugs for multiple sclerosis have become available in recent years, after demonstrating efficacy in clinical trials. In the real-world setting, however, disease-modifying drugs are prescribed in patient populations that differ from those included in pivotal studies, where extreme age patients are usually excluded or under-represented. In this multicentre, observational, retrospective Italian cohort study, we evaluated treatment exposure in three cohorts of patients with relapsing-remitting multiple sclerosis defined by age at onset: paediatric-onset (≤18 years), adult-onset (18–49 years) and late-onset multiple sclerosis (≥50 years). We…

AdultMalemedicine.medical_specialtyneuroinflammationCohort Studies03 medical and health sciences0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicinemedicineHumansDisabled Persons030212 general & internal medicineProspective StudiesRisk factorclinical trials; clinically isolated syndrome; demyelination; multiple sclerosis epidemiology; neuroinflammationRetrospective Studiesclinical trialsClinically isolated syndromeExpanded Disability Status ScaleProportional hazards modelbusiness.industryHazard ratioMiddle AgedItalyAntirheumatic Agentsclinically isolated syndromeCohortDisease Progressionmultiple sclerosis epidemiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)demyelinationAge of onsetbusiness030217 neurology & neurosurgeryCohort studyFollow-Up Studies
researchProduct

Trajectories of Blood Pressure Elevation Preceding Hypertension Onset: An Analysis of the Framingham Heart Study Original Cohort

2018

Importance Given that hypertension remains a leading risk factor for chronic disease globally, there are substantial ongoing efforts to define the optimal range of blood pressure (BP). Objective To identify a common threshold level above which BP rise tends to accelerate in progression toward hypertension. Design, Setting, and Participants This longitudinal, community-based epidemiological cohort study of adults enrolled in Framingham, Massachusetts, included 1252 participants (mean [SD] age, 35.3 [2.7] years) from the Framingham Original Cohort, of whom 790 (63.1%) were women. Each participant contributed up to 28 serial examinations of standardized resting BP measurements between 1948 and…

AdultMalemedicine.medical_specialtysystolic blood pressuresegmented mixed modelHemodynamicsBlood Pressurethreshold value030204 cardiovascular system & hematology03 medical and health sciencesSex Factors0302 clinical medicineFramingham Heart StudyInternal medicineHumansMedicineLongitudinal Studies030212 general & internal medicineAge of OnsetRisk factorAgedAged 80 and overFramingham Risk Scorebusiness.industryBrief ReportAge FactorsMiddle Agedta3121Blood pressureMassachusettsHypertensionCohortDisease ProgressionCardiologyFemaleAge of onsetCardiology and Cardiovascular MedicinebusinessCohort study
researchProduct

Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Ita…

2018

Objective.Macrophage activation syndrome (MAS) is a reactive form of hemophagocytic lymphohistiocytosis, which can complicate adult-onset Still disease (AOSD). We investigated AOSD clinical features at the time of diagnosis, to assess predictors of MAS occurrence. Further, we analyzed the outcomes of patients with AOSD who experience MAS.Methods.Patients with AOSD admitted to any Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale center were retrospectively analyzed for features typical of AOSD, MAS occurrence, and their survival rate.Results.Of 119 patients with AOSD, 17 experienced MAS (12 at admission and 5 during followup). Twelve patients with MAS at first admission diff…

AdultMalemusculoskeletal diseases0301 basic medicineAdult onset still diseasemedicine.medical_specialtyAbdominal painMultivariate analysisSurvivalImmunologyStill DiseaseComorbidityGastroenterology03 medical and health sciences0302 clinical medicineRheumatologyInternal medicinePrevalencemedicineHumansImmunology and AllergySurvival rateRetrospective Studies030203 arthritis & rheumatologyFerritinHemophagocytic lymphohistiocytosisbiologybusiness.industryIncidencefungiMiddle AgedHyperferritinemic syndromemedicine.diseaseSurvival RateFerritin030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeFerritinsCohortbiology.proteinAdult onset still disease; Ferritin; Hyperferritinemic syndrome; Macrophage activation syndrome; Survival; Rheumatology; Immunology and Allergy; ImmunologyFemalemedicine.symptombusinessStill's Disease Adult-OnsetThe Journal of Rheumatology
researchProduct

Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 case…

2016

Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokine storm, which is involved in the development of multiple organ failure. In this paper, we investigated clinical data, treatments, and outcome of a homogeneous cohort of 41 adult MAS patients, complicating autoimmune rheumatic diseases. MAS-related death occurred in 17 patients (42.5%) during the follow-up, and older age and increased serum ferritin levels, at the time of diagnosis, were significan…

AdultMalemusculoskeletal diseases0301 basic medicinemedicine.medical_specialtyImmunologyAdult onset Still's disease; Hyperferritinemic syndrome; Macrophage activation syndrome; Adult; Ambulatory Care Facilities; Autoimmune Diseases; Female; Humans; Immunosuppressive Agents; Macrophage Activation Syndrome; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Immunology and Allergy; ImmunologyDiseaseAmbulatory Care FacilitiesAutoimmune Diseases03 medical and health sciences0302 clinical medicineAdult onset Still's diseaseInternal medicineHumansImmunology and AllergyMedicineRetrospective Studies030203 arthritis & rheumatologyAutoimmune diseaseAdult patientsbusiness.industryMortality ratefungiRetrospective cohort studyMiddle AgedPrognosisHyperferritinemic syndromemedicine.diseasebody regionsSettore MED/16 - ReumatologiaTreatment Outcome030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeCohortImmunologyFemalelipids (amino acids peptides and proteins)businessCytokine stormImmunosuppressive Agentshormones hormone substitutes and hormone antagonistsAutoimmunity Reviews
researchProduct

Identification of two novel polymorphisms and a rare deletion variant in the human dopamine D4 receptor gene

1995

We report two novel polymorphisms and a rare deletion variant in the human dopaine D4 receptor gene. The two polymorphisms are characterized by single base pair substitutions, namely a G-->C transversion changing codon 11 from GGG (encoding Gly) to CGG (encoding Arg) and a C-->T transition in position -11 upstream from the start codon. The Arg11 variant occurs at a frequency of about 1% and the C-->T transition at a frequency of about 7% in German control subjects (n = 148). Allele frequencies observed in patients suffering from schizophrenia (n = 256) and bipolar affective disorder (n = 99) were similar. The deletion variant is characterized by a 21 bp deletion affecting codons 36 to 42 co…

AdultObsessive-Compulsive DisorderBipolar DisorderMolecular Sequence DataBiologymedicine.disease_causePolymerase Chain ReactionGene FrequencyStart codonReference ValuesLeukocytesGeneticsmedicineHumansPoint MutationAmino Acid SequenceAge of OnsetCodonTransversionGeneAllele frequencyBiological PsychiatryGenetics (clinical)DNA PrimersRepetitive Sequences Nucleic AcidSequence DeletionGeneticsMutationBase SequenceTransition (genetics)Receptors Dopamine D2Receptors Dopamine D4Genetic VariationDNAExonsMiddle Agedmedicine.diseasePsychiatry and Mental healthTransmembrane domainSchizophreniaSchizophreniaPanic DisorderPolymorphism Restriction Fragment Length
researchProduct

Current state of clinical and morphological features in human NCL.

2004

The neuronal ceroid lipofuscinoses (NCL) are large group of autosomal recessive lysosomal storage disorders with both enzymatic deficiency and structural protein dysfunction. Previously, diagnosis of (NCL) was based on age at onset clinicopathological (C‐P) findings described 4 forms, classified as infantile (INCL) (2), late‐infantile (LINCL) (5), juvenile (JNCL) (6), and adult (ANCL) most patients with NCL have progressive ocular and cerebral dysfunvtion, including cognitive/motor dysfunction and uncontrolled seizures. After reviewing 520 patients with NCL, we found that about 104 (20%) did not fit this classification of NCL With further research, 4 additional forms have been recognized: F…

AdultPathologymedicine.medical_specialtymedicine.disease_causeArticlePathology and Forensic MedicineEpilepsyNeuronal Ceroid-LipofuscinosesGenotypemedicineHumansPalmitoyl protein thioesteraseAge of OnsetChildInclusion BodiesMutationbiologyTripeptidyl-Peptidase 1General NeurosciencePPT1Infantmedicine.diseasePhenotypeCLN8Child PreschoolMutationbiology.proteinNeurology (clinical)Age of onsetBrain pathology (Zurich, Switzerland)
researchProduct

Sudden upper airway obstruction in patients with hereditary angioedema.

2003

Hereditary angioedema (HAE) is clinically characterized by recurrent and self-limiting skin, intestinal, and life-threatening laryngeal edema. This study describes the age at which laryngeal edema first occurred, the time between onset and full development, and the effectiveness of therapy and prophylaxis in 123 HAE patients. 61 (49.7%) patients experienced a total of 596 laryngeal edema episodes. The ratio of laryngeal edema episodes to skin swellings and abdominal pain attacks was approximately 1:70:54 in patients who had laryngeal edema. The mean (SD) age at the first laryngeal edema was 26.2 (15.3) years. Nearly 80% of the laryngeal edemas occurred between age 11 and 45. The mean interv…

AdultRiskAbdominal painmedicine.medical_specialtyTime FactorsAdolescentComplement C1 Inactivator ProteinsLaryngeal EdemaC1-inhibitormedicineHumansYoung adultAge of OnsetAngioedemaChildDanazolbiologybusiness.industryAge FactorsHematologyAirway obstructionLaryngeal EdemaMiddle Agedmedicine.diseaseSurgeryAirway ObstructionAnesthesiaHereditary angioedemaAcute Diseasebiology.proteinmedicine.symptomAge of onsetbusinessmedicine.drugTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
researchProduct

Somatosensory evoked potentials in Arnold-Chiari malformation.

2002

Abstract Nearly all patients with repaired myelomeningoceles have an Arnold–Chiari (AC) malformation and about 20% of these patients develop clinical signs of brainstem dysfunction. The management of symptomatic AC malformation is still controversial and techniques are needed to provide an objective assessment of brainstem function. We recorded somatosensory evoked potentials (SEPs) in 52 patients aged between 8 months and 20 years (median 7.3 years) with AC malformation, to determine whether the SEPs discriminate patients with symptomatic AC malformation from those without symptoms. The subcortical far-field components P13, P14 and N18, which are generated within the brainstem, were record…

AdultYounger ageMeningomyeloceleAdolescentNeural ConductionSigns and symptomsLate onsetSomatosensory systemSensitivity and SpecificityDevelopmental NeurosciencePredictive Value of TestsEvoked Potentials SomatosensoryMedicineHumansIn patientChildbusiness.industryInfantReproducibility of ResultsGeneral MedicineArnold-Chiari MalformationSpinal CordSomatosensory evoked potentialAnesthesiaChild PreschoolPediatrics Perinatology and Child HealthNeurology (clinical)BrainstemArnold chiaribusinessBrain StemBraindevelopment
researchProduct

Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

1994

Objective To determine the effectiveness of GnRH-agonist (GnRH-a) treatment in women with late onset congenital adrenal hyperplasia. Design Prospective assessment of GnRH-a treatment in six women with documented late-on-set congenital adrenal hyperplasia who were not preselected. Comparisons were made to previous responses in the same patients receiving dexamethasone. Eight age- and weight-matched ovulatory women served as controls. Setting Academic medical center. Intervention Baseline blood determinations before and after IV ACTH, before and after 6months of GnRH-a treatment. Estrogen and progestin replacement was begun in all women after the 3rd month of treatment. Main Outcome Measures …

Adultendocrine systemmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classOvaryDexamethasoneInternal medicineEndocrine GlandsmedicineHydroxyprogesteronesHumansCongenital adrenal hyperplasiaProspective StudiesAge of OnsethirsutismDexamethasoneTriptorelin PamoatebiologyAdrenal Hyperplasia Congenitalbusiness.industry17-alpha-HydroxyprogesteroneOvary21-HydroxylaseObstetrics and Gynecologymedicine.diseaseAndrogenmedicine.anatomical_structureEndocrinologyReproductive MedicineEstrogenbiology.proteinAndrogensFemalebusinessProgestinhormones hormone substitutes and hormone antagonistsGonadotropinsmedicine.drugFertility and sterility
researchProduct

Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy.

2009

Background Hereditary angioedema caused by mutations in the factor XII gene is a recently described disease entity that occurs mainly in women. It differs from hereditary angioedema caused by C1 inhibitor deficiency. Objective To assess the clinical symptoms, factors triggering acute attacks, and treatments of this disease. Methods Thirty-five female patients with hereditary angioedema and the factor XII mutations p.Thr309Lys and p.Thr309Arg who came from 13 unrelated families were studied. The observation period was 8.4 years on average (range, 2-26 years). Results Patients had on average 12.7 ± 7.9 angioedema attacks per year. Recurrent facial swellings occurred in all patients; skin swel…

Adultmedicine.medical_specialtyAbdominal painAdolescentmedicine.medical_treatmentImmunologyMutation MissenseSeverity of Illness IndexC1-inhibitorYoung AdultRisk FactorsSurveys and QuestionnairesImmunology and AllergyMedicineHumansHereditary Angioedema Type IIIAge of OnsetChildProgesteroneDanazolPregnancyAngioedemabiologybusiness.industryDanazolAngioedemas HereditaryHormone replacement therapy (menopause)Middle Agedmedicine.diseaseDermatologySurgeryPedigreeTranexamic AcidHereditary angioedemaFactor XIIbiology.proteinFemalemedicine.symptombusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct